Mechanistically, miR-29a was shown to suppress MYBL2 translation by directly binding to its 3<sup>'</sup>-UTR; this was validated <i>in vivo</i>, where miR-29a transgenic mice were protected from WD/CCl<sub>4</sub>-induced HCC, demonstrating reduced tumor burden, MYBL2 expression, and fibrosis. The gene discussed is MYBL2; the disease is Wilson disease.